Authors' Responses

REFERENCES

• Chang , M. N. , Hwang , I. K. , and Shih , W. J. ( 1998 ). Group Sequential Designs Using Both Type I and Type II Error Probability Spending Functions, Communications in Statistics—Theory & Methods 27 : 1323 – 1339 .
   Web of Science ®Google Scholar
• Lan , K. K. G. and DeMets , D. L. ( 1983 ). Discrete Sequential Boundaries for Clinical Trials, Biometrika 70 : 659 – 663 .
   Web of Science ®Google Scholar
• Mor , M. K. and Anderson , S. J. ( 2005 ). A Bayesian Group Sequential Approach for Multiple Endpoints, Sequential Analysis 24 : 45 – 62 .
   Google Scholar
• Temple , R. and Ellenberg , S. ( 2000 ). Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues, Annals of Internal Medicine 133 : 455 – 463 .
   PubMed Web of Science ®Google Scholar
• Wheatley , K. and Clayton , D. ( 2003 ). Be Skeptical about Unexpected Large Apparent Treatment Effects: The Case of an MRC AML 12 Randomization , Controlled Clinical Trials 24 : 66 – 70 .
   PubMedGoogle Scholar
• Recommended by N. Mukhopadhyay
   Google Scholar